AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04796779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology Pro
Description: The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population.
Study NCT04796779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (SC)
Description: Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
Study NCT04796779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology V1.5
Description: The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features.
Study NCT04796779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tandem t:slim X2 with Control-IQ Technology V1.5
Description: The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features.
Study NCT05162365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314
Description: Low/medium/high dose, intravenously, once, on Day 1
Study NCT05162365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, intravenously, once, on Day 1
Study NCT05414032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
Study NCT00666783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
Study NCT00666783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
Study NCT05529251 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3 cycles of EP
Description: 3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
Study NCT04874584 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Chemotherapy Education
Description: Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
Study NCT05636059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: 32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
Study NCT05636059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + cryotherapy
Description: Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
Study NCT06507085 — intervention group
Intervention type: RADIATION
Intervention: Radio-guided interventions to correct heart rhythm disorders
Description: All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate
Study NCT05456412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JAK inhibitor treatment
Description: Standard care
Study NCT05679609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
Study NCT06526806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot game strategy
Description: Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course.
Study NCT06187311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Study NCT06187311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG
Description: Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Study NCT05588180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FVD/FAD ratio guided
Description: Ultrasound-guided ratio
Study NCT05588180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV
Description: PPV
Study NCT05957588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proning group
Description: Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed.
Study NCT05957588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
Study NCT04994080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol QD Treatment
Study NCT04994080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD or TIW
Study NCT04813276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Together serious game
Description: The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
Study NCT05734664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsify sensor
Description: A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
Study NCT05734664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: State-of-the-art ultrasound equipment
Description: A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
Study NCT04813276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care as Usual
Description: A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
Study NCT06207695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Group Intervention
Description: This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
Study NCT06313853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH-Cog
Description: Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
Study NCT05950971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone, diltiazem or esmolol
Description: Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
Study NCT06403748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.
Description: The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].
Study NCT06403748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04871230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3G DBS
Description: Collection of capillary blood samples for the 3G q-PCR test
Study NCT04871230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum Test
Description: Collection of sputum for test culture, microscopy, GeneXpert
Study NCT04871230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3G Veinous Blood
Description: Collection liquid veinous blood for the 3G q-PCR test
Study NCT05579119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100 mg po once daily.
Study NCT05579119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine once daily.
Study NCT05579119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Glargine once daily.
Study NCT05579119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
Study NCT05579119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
Study NCT05226897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC405-T
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05226897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05226897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05226897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05226897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05226897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YYC405-T placebo
Description: Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
Study NCT05636059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + joint mobilization
Description: Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
Study NCT04656392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath test (eNose) followed by uTNE.
Description: All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
Study NCT06411223 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative drug therapy management model
Description: CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.
Study NCT06411223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cabotegravir/Rilpivirine
Description: Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
Study NCT06119451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Music Therapy
Description: Intervention using traditional music therapy as an alternative therapy for burnout syndrome
Study NCT05439018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular inhibition
Description: Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
Study NCT05439018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
Study NCT05145712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bowel readiness
Description: During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year
Study NCT06178367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight hyaluronic acid
Description: Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
Study NCT06178367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High molecular weight hyaluronic acid
Description: Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
Study NCT06178367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
Study NCT04915508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: Receive hormonal therapy
Study NCT04915508 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05185401 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Retrospective data-analysis
Study NCT06302465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide
Description: Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
Study NCT06302465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin、cisplatin、methotrexate、ifosfamide
Description: doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
Study NCT05461599 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SparkRx Mobile App
Description: The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.